Loading…
Pacific Biosciences of California, Inc. is projected to rise to $1.56 by 2027, a +12% move from its current price of $1.40. PACB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $1.35 | $1.40 | $1.45 | -0.06% |
| Aug 4 | $1.33 | $1.40 | $1.47 | -0.11% |
| Aug 5 | $1.32 | $1.40 | $1.48 | -0.17% |
| Aug 6 | $1.30 | $1.40 | $1.50 | -0.22% |
| Aug 7 | $1.29 | $1.40 | $1.51 | -0.28% |
| Aug 8 | $1.28 | $1.40 | $1.52 | -0.34% |
| Aug 9 | $1.27 | $1.39 | $1.53 | -0.39% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.27 | $1.39 | $1.53 | -0.39% |
| Week 2 | $1.22 | $1.39 | $1.58 | -0.78% |
| Week 3 | $1.18 | $1.38 | $1.62 | -1.17% |
| Week 4 | $1.15 | $1.38 | $1.65 | -1.56% |
| Week 5 | $1.12 | $1.37 | $1.68 | -1.94% |
| Week 6 | $1.09 | $1.37 | $1.71 | -2.33% |
| Week 7 | $1.07 | $1.36 | $1.73 | -2.71% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.
It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies.
The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data.
The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Pacific Biosciences of California, Inc. (PACB) operates in the healthcare sector and designs and manufactures sequencing solutions for complex genetic problems. The stock is currently priced at $1.44 with a market cap of $447.27M and a market position of rank 3016.
The price outlook spans a long horizon, with a series of year-by-year forecasts showing gradual to strong upside through 2050, including a 2050 avg of $10.63 and a 638.3 ROI. The company’s product line includes SMRT technology, long-read sequencing, and instruments such as Revio, Vega, and Sequel, complemented by kits and reagents for sequencing workflows.
A major floor 24.8% below — a decisive break under it would weaken the trend.
The nearest floor, 6.4% below — buyers have tended to step in here.
The nearest ceiling, 24.3% above — a clean break opens room to run.
A major ceiling 36.7% above — clearing it would confirm fresh momentum.
Key PACB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PACB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.41 | Sell | $1.41 | Sell |
| MA 10 | $1.39 | Buy | $1.42 | Sell |
| MA 20 | $1.46 | Sell | $1.44 | Sell |
| MA 50 | $1.45 | Sell | $1.46 | Sell |
| MA 100 | $1.44 | Sell | $1.50 | Sell |
| MA 200 | $1.71 | Sell | $1.58 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.94 | Neutral |
| Stoch RSI (14) | 46.09 | Neutral |
| CCI (20) | -56.82 | Neutral |
| Williams %R (14) | -76.47 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -8.50 | Sell |
| Bollinger %B (20,2) | 0.32 | Neutral |
| Stochastic %K (14) | 23.53 | Neutral |
| TRIX (15) | -0.17 | Sell |
| Awesome (5,34) | -0.07 | Sell |
| Ultimate (7,14,28) | 50.14 | Neutral |
| Momentum (10) | -0.04 | Sell |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 1.44 | Sell |
| ADX (14) | 12.06 | Neutral |
| ATR (14) | 0.05 | Info |
The 30-day technical picture isNeutral with RSI at 50. The 50-day simple moving average sits at $1.44, while the 200-day simple moving average sits at $1.71. Near-term support is identified at $1.31 and resistance at $1.74.
Over the last 30 days, the price has traded within a range of $1.12 to $1.85, reflecting a balanced short-term setup and a relatively tight trading band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.12 | $1.40 | $1.58 | 0% | Neutral | |
| $1.22 | $1.56 | $2.14 | +12% | Neutral | |
| $1.40 | $1.87 | $2.68 | +34% | Bullish | |
| $1.54 | $2.12 | $3.14 | +51% | Bullish | |
| $1.68 | $2.37 | $3.62 | +69% | Bullish | |
| $1.65 | $2.38 | $3.74 | +70% | Bullish | |
| $1.68 | $2.49 | $3.99 | +78% | Bullish | |
| $1.68 | $2.54 | $4.16 | +82% | Bullish | |
| $1.75 | $2.70 | $4.50 | +93% | Bullish | |
| $2.21 | $3.48 | $5.90 | +148% | Bullish | |
| $2.56 | $4.42 | $8.06 | +215% | Bullish | |
| $4.50 | $9.14 | $18.51 | +553% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.12 | $1.40 | $1.62 | +0.00% |
| September 2026 | $1.10 | $1.31 | $1.61 | -6.60% |
| October 2026 | $1.11 | $1.33 | $1.66 | +1.73% |
| November 2026 | $1.07 | $1.30 | $1.63 | -2.62% |
| December 2026 | $1.02 | $1.25 | $1.58 | -3.89% |
Click any year to see its month-by-month PACB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect PACB to range from $1.12 to $1.58 through 2026. The $1.40 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The PACB price prediction for 2027 points to an average of $1.56 (low $1.22, high $2.14) — a potential gain of +12% on today's $1.40. Price action looks broadly range-bound.
In 2028, PACB is projected to trade between $1.40 and $2.68, averaging $1.87 — a potential gain of +34% from today's $1.40. That is up +20% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Pacific Biosciences of California, Inc.'s 2029 outlook centres on $2.12, within a $1.54 to $3.14 range. That is up +13% on the projected 2028 average. That marks a +51% change versus current levels. Momentum favours further upside here.
By 2030, PACB could reach as high as $3.62, with a base case around $2.37 and support toward $1.68 — roughly +69% from $1.40. Buyers look set to stay in control over this stretch.
Expect PACB to range from $1.65 to $3.74 through 2031. The $2.38 average target implies a +70% move from current prices. That is up +1% on the projected 2030 average. Momentum favours further upside here.
The PACB price prediction for 2032 points to an average of $2.49 (low $1.68, high $3.99) — a potential gain of +78% on today's $1.40. Buyers look set to stay in control over this stretch.
In 2033, PACB is projected to trade between $1.68 and $4.16, averaging $2.54 — a potential gain of +82% from today's $1.40. That is up +2% on the projected 2032 average. Momentum favours further upside here.
Pacific Biosciences of California, Inc.'s 2034 outlook centres on $2.70, within a $1.75 to $4.50 range. That is up +6% on the projected 2033 average. That marks a +93% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, PACB could reach as high as $5.90, with a base case around $3.48 and support toward $2.21 — roughly +148% from $1.40. Momentum favours further upside here.
Expect PACB to range from $2.56 to $8.06 through 2040. The $4.42 average target implies a +215% move from current prices. That is up +27% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The PACB price prediction for 2050 points to an average of $9.14 (low $4.50, high $18.51) — a potential gain of +553% on today's $1.40. Momentum favours further upside here.
Investing $1,000 in PACB today (≈ 714.285714 PACB) could be worth
$6,531.78
+$5,531.78 (+553%) by 2050 · US Dollar
Based on the average projected PACB price of $9.14 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PACBwould be worth at today's price.
$1,000 invested in PACB on Jul 31, 2025 (≈ 724.637684 PACB) would be worth
$1,014.49
+$14.49 (+1.4%) today · 1.01× · US Dollar
Based on a PACB entry price of $1.38 vs. today's $1.4.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.36 | $1,029.41 | +2.9% |
| 1 month ago | $1.74 | $804.6 | -19.5% |
| 3 months ago | $1.6 | $875 | -12.5% |
| 6 months ago | $2.06 | $679.61 | -32.0% |
| 1 year ago | $1.38 | $1,014.49 | +1.4% |
| All time (5.0y) ago | $30.21 | $46.34 | -95.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PACB forecast.
Our base-case forecast reaches $2.80 around 2035.
Implied market cap at $2.80: $869.68M
The multi-year forecast shows a path from a 2026 avg of $1.44 to higher levels, with notable milestones in 2030 (avg $2.62; ROI 82.2), 2040 (avg $4.82; ROI 235), and 2050 (avg $10.63; ROI 638.3). Bullish sentiment appears from 2027 onward, with increasing averages and ROI through 2050 and beyond, capped by higher maximums in later years (e.g., 2035 avg $3.98; max $6.99; 2040 max $9.14; 2050 max $22.50). While the forecast indicates substantial upside, these are estimates and not guarantees, and risks remain inherent in long-horizon projections with varying market and operational factors.
Tap a question to reveal the answer.
Avg $2.62; min $1.81; max $4.12; ROI 82.2; sentiment BULLISH.
The long-term forecast shows bullish momentum with increasing averages and a high potential ROI by 2050 (avg $10.63; ROI 638.3), though 2026 is neutral and outcomes are not guaranteed.
Yes, the year-by-year forecast includes higher max values such as 2035 max $6.99 and 2040 max $9.14, with a 2050 max of $22.50.
Current price $1.44; market cap $447.27M.
Sentiment NEUTRAL; RSI 14 is 50; SMA50 is $1.44; SMA200 is $1.71; 30-day range is $1.12 to $1.85; support $1.31; resistance $1.74.
Pacific Biosciences of California, Inc. Community Discussion
0Share your Pacific Biosciences of California, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.